- Home
- Making Gains in HFpEF: An Appraisal of Where We Are Now
Making Gains in HFpEF: An Appraisal of Where We Are Now
- Heart Failure
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
In this symposium, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with a left ventricular ejection fraction >40%. In addition to hearing about the data which led to changes in the recent ACC guidelines, we’ll also explore the impact of clinical inertia and the remaining challenges in HFpEF management.
This symposium is part of Heart Failure Online 2022, a world-class virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes.
Support Statement
This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. The scientific programme has not been influenced in any way by the sponsors.
It is not intended for US or UK based healthcare professionals.
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
Learning Objectives
Upon participation in this programme physicians will be able to:
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Presentation & Discussion | Patient Case: Typical Patient with HFpEF | 15 mins | Shelley Zieroth (Manitoba, CA) |
| Presentation & Discussion | SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell | 15 mins | Javed Butler (Texas, US) |
| Presentation & Discussion | Early Initiation of Foundational Therapy in HF: Why The Urgency? | 15 mins | Carolyn Lam (Singapore, SG) |
SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell
Duration: 15 mins
Speakers: Javed Butler (Texas, US)
Early Initiation of Foundational Therapy in HF: Why The Urgency?
Duration: 15 mins
Speakers: Carolyn Lam (Singapore, SG)
Related Courses
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- 1.00
Published:
Learning objectives
- To differentiate ATTR phenotypes based on presenting signs and symptoms.
- To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
- To recall how to identify disease progression across ATTR-cm.
- To describe the different disease modifying treatments for ATTR including novel agents.
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
- 1.00
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice